UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2015 UpToDate®

Cutaneous manifestations of internal malignancy

Author
Cindy Owen, MD
Section Editor
Jeffrey Callen, MD, FACP, FAAD
Deputy Editor
Abena O Ofori, MD

INTRODUCTION

The cutaneous manifestations of internal malignancy include a wide variety of nonmalignant skin disorders that occur in association with malignancy (paraneoplastic dermatoses) and skin disorders that represent infiltration of malignant cells into the skin due to metastatic or locoregional spread of disease or the deposition of circulating tumor cells (eg, leukemia cutis) [1,2]. When paraneoplastic dermatoses develop before an internal neoplasm is diagnosed, recognition of these disorders can aid in the diagnosis of the malignancy.

PARANEOPLASTIC DERMATOSES

Paraneoplastic dermatoses are a group of skin disorders that have strong associations with internal malignancies. Curth's postulates can aid in the classification of dermatoses as paraneoplastic (table 1) [1]. Cutaneous findings resulting from the entry of tumor cells into the skin are not considered paraneoplastic dermatoses. (See 'Non-paraneoplastic cutaneous manifestations of internal malignancy' below.)

The paraneoplastic dermatoses reviewed below are organized according to common clinical features. Some of these dermatoses may also develop in the absence of malignancy. However, the detection of a potential paraneoplastic dermatosis warrants consideration of the possibility of malignancy.

Hyperkeratotic and proliferative dermatoses — Acanthosis nigricans, the sign of Leser-Trélat, tripe palm, acquired ichthyosis, and palmoplantar keratoderma are examples of paraneoplastic disorders that present with clinical features of hyperkeratosis or epidermal proliferation.

Acanthosis nigricans — Acanthosis nigricans is a reactive skin pattern that typically presents as velvety to verrucous hyperpigmented plaques in intertriginous areas (picture 1A-D). While the majority of cases of acanthosis nigricans are benign and associated with obesity and insulin resistance, the disease also can herald the onset of malignancy. (See "Acanthosis nigricans".)

                                    

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Mar 2015. | This topic last updated: Feb 26, 2015.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2015 UpToDate, Inc.
References
Top
  1. Thiers BH, Sahn RE, Callen JP. Cutaneous manifestations of internal malignancy. CA Cancer J Clin 2009; 59:73.
  2. Ehst BD, Minzer-Conzetti K, Swerdlin A, Devere TS. Cutaneous manifestations of internal malignancy. Curr Probl Surg 2010; 47:384.
  3. Krawczyk M, Mykała-Cieśla J, Kołodziej-Jaskuła A. Acanthosis nigricans as a paraneoplastic syndrome. Case reports and review of literature. Pol Arch Med Wewn 2009; 119:180.
  4. Kamińska-Winciorek G, Brzezińska-Wcisło L, Lis-Swiety A, Krauze E. Paraneoplastic type of acanthosis nigricans in patient with hepatocellular carcinoma. Adv Med Sci 2007; 52:254.
  5. Serap D, Ozlem S, Melike Y, et al. Acanthosis nigricans in a patient with lung cancer: a case report. Case Rep Med 2010; 2010.
  6. Oh CW, Yoon J, Kim CY. Malignant Acanthosis Nigricans Associated with Ovarian Cancer. Case Rep Dermatol 2010; 2:103.
  7. Longshore SJ, Taylor JS, Kennedy A, Nurko S. Malignant acanthosis nigricans and endometrioid adenocarcinoma of the parametrium: the search for malignancy. J Am Acad Dermatol 2003; 49:541.
  8. Moscardi JL, Macedo NA, Espasandin JA, Piñeyro MI. Malignant acanthosis nigricans associated with a renal tumor. Int J Dermatol 1993; 32:893.
  9. Rigel DS, Jacobs MI. Malignant acanthosis nigricans: a review. J Dermatol Surg Oncol 1980; 6:923.
  10. Brown J, Winkelmann RK. Acanthosis nigricans: a study of 90 cases. Medicine (Baltimore) 1968; 47:33.
  11. Yeh JS, Munn SE, Plunkett TA, et al. Coexistence of acanthosis nigricans and the sign of Leser-Trélat in a patient with gastric adenocarcinoma: a case report and literature review. J Am Acad Dermatol 2000; 42:357.
  12. Heaphy MR Jr, Millns JL, Schroeter AL. The sign of Leser-Trélat in a case of adenocarcinoma of the lung. J Am Acad Dermatol 2000; 43:386.
  13. Ellis DL, Kafka SP, Chow JC, et al. Melanoma, growth factors, acanthosis nigricans, the sign of Leser-Trélat, and multiple acrochordons. A possible role for alpha-transforming growth factor in cutaneous paraneoplastic syndromes. N Engl J Med 1987; 317:1582.
  14. Kurzrock R, Cohen PR. Cutaneous paraneoplastic syndromes in solid tumors. Am J Med 1995; 99:662.
  15. Schwartz RA. Sign of Leser-Trélat. J Am Acad Dermatol 1996; 35:88.
  16. Gregory B, Ho VC. Cutaneous manifestations of gastrointestinal disorders. Part II. J Am Acad Dermatol 1992; 26:371.
  17. Husain Z, Ho JK, Hantash BM. Sign and pseudo-sign of Leser-Trélat: case reports and a review of the literature. J Drugs Dermatol 2013; 12:e79.
  18. Shah KR, Boland CR, Patel M, et al. Cutaneous manifestations of gastrointestinal disease: part I. J Am Acad Dermatol 2013; 68:189.e1.
  19. Güngör S, Topal I. Images in clinical medicine. Tripe palms. N Engl J Med 2014; 370:558.
  20. Cohen PR, Grossman ME, Almeida L, Kurzrock R. Tripe palms and malignancy. J Clin Oncol 1989; 7:669.
  21. Ameen M, Chopra S, Darvay A, et al. Erythema gyratum repens and acquired ichthyosis associated with transitional cell carcinoma of the kidney. Clin Exp Dermatol 2001; 26:510.
  22. Patel N, Spencer LA, English JC 3rd, Zirwas MJ. Acquired ichthyosis. J Am Acad Dermatol 2006; 55:647.
  23. Riesco Martínez MC, Muñoz Martín AJ, Zamberk Majlis P, et al. Acquired ichthyosis as a paraneoplastic syndrome in Hodgkin's disease. Clin Transl Oncol 2009; 11:552.
  24. Rabhi M, Ennibi K, Harket A, et al. Acquired ichthyosis disclosing non-Hodgkin's malignant lymphoma. Intern Med 2007; 46:397.
  25. Word AP, Cayce R, Pandya AG. Beware of underlying malignancy: acquired ichthyosis. Am J Med 2014; 127:202.
  26. Spelman LJ, Strutton GM, Robertson IM, Weedon D. Acquired ichthyosis in bone marrow transplant recipients. J Am Acad Dermatol 1996; 35:17.
  27. Kleyn CE, Lai-Cheong JE, Bell HK. Cutaneous manifestations of internal malignancy: diagnosis and management. Am J Clin Dermatol 2006; 7:71.
  28. Braun-Falco M. Hereditary palmoplantar keratodermas. J Dtsch Dermatol Ges 2009; 7:971.
  29. Itin PH, Lautenschlager S. Palmoplantar keratoderma and associated syndromes. Semin Dermatol 1995; 14:152.
  30. Kim ST, Jeon YS, Sim HJ, et al. Clinicopathologic features and T-cell receptor gene rearrangement findings of mycosis fungoides palmaris et plantaris. J Am Acad Dermatol 2006; 54:466.
  31. Itin PH, Fistarol SK. Palmoplantar keratodermas. Clin Dermatol 2005; 23:15.
  32. Richard M, Giroux JM. Acrokeratosis paraneoplastica (Bazex' syndrome). J Am Acad Dermatol 1987; 16:178.
  33. Lucker GP, Steijlen PM. Acrokeratosis paraneoplastica (Bazex syndrome) occurring with acquired ichthyosis in Hodgkin's disease. Br J Dermatol 1995; 133:322.
  34. Bolognia JL, Brewer YP, Cooper DL. Bazex syndrome (acrokeratosis paraneoplastica). An analytic review. Medicine (Baltimore) 1991; 70:269.
  35. Sator PG, Breier F, Gschnait F. Acrokeratosis paraneoplastica (Bazex's syndrome): association with liposarcoma. J Am Acad Dermatol 2006; 55:1103.
  36. Taher M, Grewal P, Gunn B, et al. Acrokeratosis paraneoplastica (Bazex syndrome) presenting in a patient with metastatic breast carcinoma: possible etiologic role of zinc. J Cutan Med Surg 2007; 11:78.
  37. Fleming JD, Stefanato CM, Attard NR. Bazex syndrome (acrokeratosis paraneoplastica). Clin Exp Dermatol 2014; 39:955.
  38. Bolognia JL. Bazex syndrome: acrokeratosis paraneoplastica. Semin Dermatol 1995; 14:84.
  39. Crucitti A, Feliciani C, Grossi U, et al. Paraneoplastic acrokeratosis (bazex syndrome) in lung cancer. J Clin Oncol 2009; 27:e266.
  40. Fasanmade A, Farrell K, Perkins CS. Bazex syndrome (acrokeratosis paraneoplastica): persistence of cutaneous lesions after successful treatment of an associated oropharyngeal neoplasm. Br J Oral Maxillofac Surg 2009; 47:138.
  41. Cohen PR, Kurzrock R. Sweet's syndrome revisited: a review of disease concepts. Int J Dermatol 2003; 42:761.
  42. Cohen PR, Kurzrock R. Sweet's syndrome and cancer. Clin Dermatol 1993; 11:149.
  43. Nicolis GD, Helwig EB. Exfoliative dermatitis. A clinicopathologic study of 135 cases. Arch Dermatol 1973; 108:788.
  44. King LE Jr, Dufresne RG Jr, Lovett GL, Rosin MA. Erythroderma: review of 82 cases. South Med J 1986; 79:1210.
  45. Nousari HC, Kimyai-Asadi A, Spegman DJ. Paraneoplastic dermatomyositis presenting as erythroderma. J Am Acad Dermatol 1998; 39:653.
  46. Appell ML, Ward WQ, Tyring SK. Erythema gyratum repens. A cutaneous marker of malignancy. Cancer 1988; 62:548.
  47. Eubanks LE, McBurney E, Reed R. Erythema gyratum repens. Am J Med Sci 2001; 321:302.
  48. Rongioletti F, Fausti V, Parodi A. Erythema gyratum repens is not an obligate paraneoplastic disease: a systematic review of the literature and personal experience. J Eur Acad Dermatol Venereol 2014; 28:112.
  49. Demonchy E, Lacour JP, Ortonne JP, Passeron T. Erythema gyratum repens, not always a bad omen for patients. J Eur Acad Dermatol Venereol 2010; 24:738.
  50. Lobo I, Carvalho A, Amaral C, et al. Glucagonoma syndrome and necrolytic migratory erythema. Int J Dermatol 2010; 49:24.
  51. Marinkovich MP, Botella R, Datloff J, Sangueza OP. Necrolytic migratory erythema without glucagonoma in patients with liver disease. J Am Acad Dermatol 1995; 32:604.
  52. Tierney EP, Badger J. Etiology and pathogenesis of necrolytic migratory erythema: review of the literature. MedGenMed 2004; 6:4.
  53. Chastain MA. The glucagonoma syndrome: a review of its features and discussion of new perspectives. Am J Med Sci 2001; 321:306.
  54. Remes-Troche JM, García-de-Acevedo B, Zuñiga-Varga J, et al. Necrolytic migratory erythema: a cutaneous clue to glucagonoma syndrome. J Eur Acad Dermatol Venereol 2004; 18:591.
  55. García-Romero D, Vanaclocha F. Pancreatic panniculitis. Dermatol Clin 2008; 26:465.
  56. Bennett RG, Petrozzi JW. Nodular subcutaneous fat necrosis. A manifestation of silent pancreatitis. Arch Dermatol 1975; 111:896.
  57. Heykarts B, Anseeuw M, Degreef H. Panniculitis caused by acinous pancreatic carcinoma. Dermatology 1999; 198:182.
  58. Dahl PR, Su WP, Cullimore KC, Dicken CH. Pancreatic panniculitis. J Am Acad Dermatol 1995; 33:413.
  59. Lewis CT 3rd, Tschen JA, Klima M. Subcutaneous fat necrosis associated with pancreatic islet cell carcinoma. Am J Dermatopathol 1991; 13:52.
  60. van Klaveren RJ, de Mulder PH, Boerbooms AM, et al. Pancreatic carcinoma with polyarthritis, fat necrosis, and high serum lipase and trypsin activity. Gut 1990; 31:953.
  61. Nousari HC, Deterding R, Wojtczack H, et al. The mechanism of respiratory failure in paraneoplastic pemphigus. N Engl J Med 1999; 340:1406.
  62. Sehgal VN, Srivastava G. Paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome. Int J Dermatol 2009; 48:162.
  63. Anhalt GJ. Paraneoplastic pemphigus. J Investig Dermatol Symp Proc 2004; 9:29.
  64. Egan CA, Lazarova Z, Darling TN, et al. Anti-epiligrin cicatricial pemphigoid and relative risk for cancer. Lancet 2001; 357:1850.
  65. Pivonello R, De Martino MC, De Leo M, et al. Cushing's Syndrome. Endocrinol Metab Clin North Am 2008; 37:135.
  66. Wakamatsu K, Graham A, Cook D, Thody AJ. Characterisation of ACTH peptides in human skin and their activation of the melanocortin-1 receptor. Pigment Cell Res 1997; 10:288.
  67. Böhm M, Schiller M, Nashan D, et al. Diffuse melanosis arising from metastatic melanoma: pathogenetic function of elevated melanocyte peptide growth factors. J Am Acad Dermatol 2001; 44:747.
  68. Murray C, D'Intino Y, MacCormick R, et al. Melanosis in association with metastatic malignant melanoma: report of a case and a unifying concept of pathogenesis. Am J Dermatopathol 1999; 21:28.
  69. Perez A, Turajlic S, Szyszko T, et al. Generalized melanosis and melanuria in a patient with metastatic melanoma. Clin Exp Dermatol 2010; 35:e37.
  70. Spremulli EN, Bogaars HA, Dexter DL, et al. Nude mouse model of the melanosis syndrome. J Natl Cancer Inst 1983; 71:933.
  71. Steiner A, Rappersberger K, Groh V, Pehamberger H. Diffuse melanosis in metastatic malignant melanoma. J Am Acad Dermatol 1991; 24:625.
  72. Fain O, Hamidou M, Cacoub P, et al. Vasculitides associated with malignancies: analysis of sixty patients. Arthritis Rheum 2007; 57:1473.
  73. Wooten MD, Jasin HE. Vasculitis and lymphoproliferative diseases. Semin Arthritis Rheum 1996; 26:564.
  74. El Tal AK, Tannous Z. Cutaneous vascular disorders associated with internal malignancy. Dermatol Clin 2008; 26:45.
  75. Podjasek JO, Wetter DA, Pittelkow MR, Wada DA. Cutaneous small-vessel vasculitis associated with solid organ malignancies: the Mayo Clinic experience, 1996 to 2009. J Am Acad Dermatol 2012; 66:e55.
  76. Kurzrock R, Cohen PR, Markowitz A. Clinical manifestations of vasculitis in patients with solid tumors. A case report and review of the literature. Arch Intern Med 1994; 154:334.
  77. Solans-Laqué R, Bosch-Gil JA, Pérez-Bocanegra C, et al. Paraneoplastic vasculitis in patients with solid tumors: report of 15 cases. J Rheumatol 2008; 35:294.
  78. Beers WH, Ince A, Moore TL. Scleredema adultorum of Buschke: a case report and review of the literature. Semin Arthritis Rheum 2006; 35:355.
  79. Cokonis Georgakis CD, Falasca G, Georgakis A, Heymann WR. Scleromyxedema. Clin Dermatol 2006; 24:493.
  80. Rongioletti F, Rebora A. Updated classification of papular mucinosis, lichen myxedematosus, and scleromyxedema. J Am Acad Dermatol 2001; 44:273.
  81. Kitamura W, Matsuoka Y, Miyagawa S, Sakamoto K. Immunochemical analysis of the monoclonal paraprotein in scleromyxedema. J Invest Dermatol 1978; 70:305.
  82. Gabriel SE, Perry HO, Oleson GB, Bowles CA. Scleromyxedema: a scleroderma-like disorder with systemic manifestations. Medicine (Baltimore) 1988; 67:58.
  83. Kövary PM, Vakilzadeh F, Macher E, et al. Monoclonal gammopathy in scleredema. Observations in three cases. Arch Dermatol 1981; 117:536.
  84. Pujol JA, Bueno M, Fuertes MA, et al. Improvement of scleredema associated with IgA multiple myeloma after chemotherapy. Clin Exp Dermatol 1995; 20:149.
  85. Hodak E, Tamir R, David M, et al. Scleredema adultorum associated with IgG-kappa multiple myeloma--a case report and review of the literature. Clin Exp Dermatol 1988; 13:271.
  86. Vulink AJ, ten Bokkel Huinink D. Acquired hypertrichosis lanuginosa: a rare cutaneous paraneoplastic syndrome. J Clin Oncol 2007; 25:1625.
  87. Slee PH, van der Waal RI, Schagen van Leeuwen JH, et al. Paraneoplastic hypertrichosis lanuginosa acquisita: uncommon or overlooked? Br J Dermatol 2007; 157:1087.
  88. Worsnop F, Campalani E. Paraneoplastic hypertrichosis lanuginosa acquisita: a delayed presentation in quiescent chronic lymphocytic leukaemia. Clin Exp Dermatol 2014; 39:669.
  89. Pérez-Losada E, Pujol RM, Domingo P, et al. Hypertrichosis lanuginosa acquisita preceding extraskeletal Ewing's sarcoma. Clin Exp Dermatol 2001; 26:182.
  90. Mendiratta V, Harjai B, Gupta T. Hypertrichosis lanuginosa congenita. Pediatr Dermatol 2008; 25:483.
  91. Sridhar KS, Lobo CF, Altman RD. Digital clubbing and lung cancer. Chest 1998; 114:1535.
  92. Ito T, Goto K, Yoh K, et al. Hypertrophic pulmonary osteoarthropathy as a paraneoplastic manifestation of lung cancer. J Thorac Oncol 2010; 5:976.
  93. Qian X, Qin J. Hypertrophic pulmonary osteoarthropathy with primary lung cancer. Oncol Lett 2014; 7:2079.
  94. Gilchrest BA. Pruritus: pathogenesis, therapy, and significance in systemic disease states. Arch Intern Med 1982; 142:101.
  95. Paul R, Paul R, Jansen CT. Itch and malignancy prognosis in generalized pruritus: a 6-year follow-up of 125 patients. J Am Acad Dermatol 1987; 16:1179.
  96. Yosipovitch G, Bernhard JD. Clinical practice. Chronic pruritus. N Engl J Med 2013; 368:1625.
  97. Snow JL, Muller SA. Malignancy-associated multicentric reticulohistiocytosis: a clinical, histological and immunophenotypic study. Br J Dermatol 1995; 133:71.
  98. Islam AD, Naguwa SM, Cheema GS, et al. Multicentric reticulohistiocytosis: a rare yet challenging disease. Clin Rev Allergy Immunol 2013; 45:281.
  99. Rosmaninho A, Fernandes I, Guimas A, et al. Diffuse plane xanthomatosis associated with monoclonal gammopathy. An Bras Dermatol 2011; 86:S50.
  100. Hu SC, Chen GS, Wu CS, et al. Rates of cutaneous metastases from different internal malignancies: experience from a Taiwanese medical center. J Am Acad Dermatol 2009; 60:379.
  101. Alcaraz I, Cerroni L, Rütten A, et al. Cutaneous metastases from internal malignancies: a clinicopathologic and immunohistochemical review. Am J Dermatopathol 2012; 34:347.
  102. Cho-Vega JH, Medeiros LJ, Prieto VG, Vega F. Leukemia cutis. Am J Clin Pathol 2008; 129:130.
  103. Cimen S, Aslan G, Lebe B, et al. Penile keratoacanthoma associated with urothelial carcinoma of the bladder in Muir-Torre syndrome. Urol Oncol 2007; 25:326.
  104. Ponti G, Ponz de Leon M. Muir-Torre syndrome. Lancet Oncol 2005; 6:980.
  105. Dores GM, Curtis RE, Toro JR, et al. Incidence of cutaneous sebaceous carcinoma and risk of associated neoplasms: insight into Muir-Torre syndrome. Cancer 2008; 113:3372.
Topic Outline

GRAPHICS